Company intelligence / Profile preview

NeuroVenti

Seoul, Korea, South

Ownership: Private
Development stage: Other

Overview

NeuroVenti is developing multi-target small molecule drug candidates for neurodevelopmental and psychiatric conditions, including a phase II-ready candidate for autism spectrum disorder. Their lead candidate for ASD (NV01-A02) has received FDA Orphan Drug Designation.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

NV01-A02

2 more assets in the full pipeline.

Request access →

Partnerships

HLB Group (investment and strategic cooperation for epilepsy, AI-driven drug platform, and non-clinical CDRO services)

Beyond the preview

Go deeper on NeuroVenti.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroVenti.

Explore the full profile